LA LABResearch Reference Document
Compound Guide
GLOW Stack 70mg — GHK-Cu + TB-500 + BPC-157
Quick Start
One Vial, Three Compounds
The 70mg GLOW Stack is a single lyophilised vial containing GHK-Cu 50mg, TB-500 10mg, and BPC-157 10mg co-formulated together. You reconstitute and draw once — every draw delivers all three compounds in fixed proportion (71.4% / 14.3% / 14.3%). Reconstituted solution has a faint blue tint from the copper ion — this is normal.
What It Is
The GLOW Stack combines three research peptides with complementary tissue-remodelling mechanisms in one vial: GHK-Cu (copper tripeptide — collagen and skin research), TB-500 (thymosin beta-4 fragment — systemic cell migration and repair), and BPC-157 (pentadecapeptide — angiogenesis and localised healing). Studied together for synergistic effects on skin, connective tissue, and wound healing.
Research Route
SubQ injection is the studied route for the combined blend. Because all three compounds are in one vial, dosing is done by total draw volume rather than per-compound. A typical research draw of 10 units (U-100) delivers ~2.33mg of total blend — see the Dosing Protocol and Reconstitution tables below for the per-compound breakdown.
Regulatory Status
None of the three compounds are FDA-approved for injectable use. Topical GHK-Cu (as Copper Tripeptide-1) is a permitted cosmetic ingredient; the injectable forms of all three are supplied for research purposes only. Not for human or veterinary therapeutic use.
Composition — 70mg Vial
| Compound | Mass / Vial | Share of Blend | Primary Research Context |
|---|---|---|---|
| GHK-Cu | 50 mg | 71.4% | Collagen remodelling, skin photoaging, copper transport |
| TB-500 (TB-4 frag.) | 10 mg | 14.3% | Systemic cell migration, tissue & muscle repair |
| BPC-157 | 10 mg | 14.3% | Angiogenesis, tendon/gut/localised repair |
| Total | 70 mg | 100% | Single lyophilised, co-formulated vial |
99% purity per compound. Third-party tested by Janoshik Analytical. Proportions are fixed in the powder — every reconstituted draw carries all three in the ratio above.
Dosing Protocol
Because the blend is fixed, protocols are defined by draw volume (units). The table shows what each daily draw delivers per compound, based on a 3 mL reconstitution (23.33 mg/mL total).
| Draw (U-100) | Volume | Total Blend | GHK-Cu | TB-500 | BPC-157 |
|---|---|---|---|---|---|
| 6 units | 0.06 mL | 1.40 mg | 1.00 mg | 0.20 mg | 0.20 mg |
| 10 units | 0.10 mL | 2.33 mg | 1.67 mg | 0.33 mg | 0.33 mg |
| 12 units | 0.12 mL | 2.80 mg | 2.00 mg | 0.40 mg | 0.40 mg |
| 15 units | 0.15 mL | 3.50 mg | 2.50 mg | 0.50 mg | 0.50 mg |
Common research protocol: 10 units once daily for 4–6 weeks, then re-evaluate. At 10 units/day a 70mg vial yields 30 doses (~30 days). This keeps the GHK-Cu component in its studied 1–2 mg/day range while delivering daily micro-amounts of TB-500 and BPC-157.
Loading vs Maintenance
TB-500 protocols in the literature often use a higher "loading" frequency (e.g. twice weekly at a larger dose) followed by maintenance. In a fixed blend this can't be isolated — daily low-dose administration is the practical compromise for a co-formulated vial. Adjust total daily units, not individual compounds.
Supplies & Reconstitution
Reconstitution Math — 70 mg Vial (3 mL BAC)
| Draw (U-100) | Total Blend | Doses / Vial |
|---|---|---|
| 6 units | 1.40 mg | 50 |
| 10 units | 2.33 mg | 30 |
| 12 units | 2.80 mg | 25 |
| 15 units | 3.50 mg | 20 |
Reconstitute the 70 mg vial with 3.0 mL bacteriostatic water (sold separately) → 23.33 mg/mL. U-100 syringe = 100 units per mL, so each unit delivers 0.233 mg of total blend. Swirl gently — do not shake. Refrigerate 2–8°C.
Reconstitution Steps
01
Warm the vial
Allow the lyophilised vial to reach room temperature (10–15 min from freezer).
02
Swab both stoppers
Wipe the tops of the peptide vial and the BAC water vial with fresh alcohol swabs. Allow to air-dry.
03
Draw 3.0 mL BAC water
Draw 3.0 mL bacteriostatic water — use a larger syringe for the full volume, or several insulin-syringe draws.
04
Inject along the wall
Run the BAC water slowly down the inside wall of the peptide vial. Do not jet directly onto the powder.
05
Swirl gently
Swirl slowly until fully dissolved. The solution will take on a faint blue tint from the copper — this is normal. Do not shake.
06
Refrigerate
Store at 2–8°C, upright, for up to 30 days. Protect from light. Discard if the colour turns yellow or if particles appear.
Mechanism of Action
GHK-Cu · Collagen & Copper
Activates TGF-β1 and collagen synthesis in fibroblasts while remodelling damaged collagen via MMP regulation. Chelates and delivers copper (Cu²⁺), a cofactor for lysyl oxidase and superoxide dismutase. Strongest human evidence is topical.
TB-500 · Cell Migration
Thymosin beta-4 fragment. Sequesters G-actin and upregulates cell migration and differentiation, studied in systemic tissue repair, muscle, and inflammation models. Distributes widely rather than acting locally.
BPC-157 · Angiogenesis
Pentadecapeptide derived from a gastric protein. Studied for VEGFR2-driven angiogenesis and FAK-paxillin cell migration, with a research focus on tendon, ligament, and gut-lining repair.
Proposed Synergy
The three are combined for overlapping but distinct repair pathways: GHK-Cu for dermal collagen, TB-500 for systemic migration, and BPC-157 for localised angiogenesis — studied together in skin and connective-tissue research contexts.
Research Notes & Contraindications
Copper Metabolism Disorders
The GHK-Cu component delivers bioavailable copper. Research protocols exclude subjects with Wilson's disease (impaired copper excretion), Menkes syndrome, or other known copper metabolism disorders. This is a clear contraindication for the blend.
Limited Injectable Human Data
Human RCT evidence is limited to topical GHK-Cu. TB-500 and BPC-157 injectable data are predominantly preclinical (animal/in-vitro). Extrapolating to a co-formulated injectable blend is not established and should be treated strictly as a research context.
Storage
| State | Temperature | Duration | Notes |
|---|---|---|---|
| Lyophilised (powder) | −20°C (freezer) | Up to 24 months | Protect from light and moisture |
| Reconstituted (liquid) | 2–8°C (refrigerator) | Up to 30 days | Faint blue colour is normal; discard if yellow or cloudy |
| Short-term (travel) | <25°C | Up to 72 hours | Avoid direct sunlight |
Disclaimer
This document is an educational research reference only. It is not medical advice, not a treatment plan, and not a recommendation to use GHK-Cu, TB-500, or BPC-157 outside of a qualified research context. Injectable evidence for these compounds is limited; the GHK-Cu component is contraindicated where a copper metabolism disorder is present. By purchasing from LA LAB you confirm you are 18+ and that products are for research purposes only.
What the Evidence Actually Covers
A blend has no evidence of its own. Whatever is known comes from studies of the individual components, each tested alone, mostly in animals. No trial has tested these compounds together in a human, and combining them does not add their evidence together — it adds their unknowns.
Who Should Avoid the GLOW Stack
| Situation | Why |
|---|---|
| Active cancer, or a recent history | Avoid. BPC-157, TB-500 and GHK-Cu all promote angiogenesis — new blood vessel growth — and cell migration. Those are the same processes a tumour uses. None of it has been studied either way. |
| Pregnancy or breastfeeding | Avoid. No safety data for any component. |
| Under 18 | Avoid. No data. |
| Wilson’s disease or a copper disorder | Applies to anything containing GHK-Cu — copper accumulates. |
| Undiagnosed lumps, moles or growths | Get them checked before starting, not after. |
| Competing athletes | BPC-157 and TB-500 are both on the WADA prohibited list. |
Frequently Asked Questions
Why blend three peptides?
Convenience — one vial, one injection, instead of three. It is not that the combination has been shown to work better than the parts.
Convenience — one vial, one injection, instead of three. It is not that the combination has been shown to work better than the parts.
Is there evidence for the combination?
No. Each component has its own animal literature; none has been tested alongside the others in a published study.
No. Each component has its own animal literature; none has been tested alongside the others in a published study.
Can I adjust the ratio?
Not in a pre-blended vial — the ratio is fixed at manufacture. Buy the components separately if you want to vary them.
Not in a pre-blended vial — the ratio is fixed at manufacture. Buy the components separately if you want to vary them.
How long before I see skin changes?
The GHK-Cu skin studies ran 8–12 weeks. Expect months.
The GHK-Cu skin studies ran 8–12 weeks. Expect months.
Can I use it with the Face Cream?
They are different routes, and nothing suggests a conflict. The topical is where the human evidence actually is.
They are different routes, and nothing suggests a conflict. The topical is where the human evidence actually is.
Why does it look blue?
Copper. That is normal for anything containing GHK-Cu.
Copper. That is normal for anything containing GHK-Cu.
Sources & Research
Sikiric P et al. Stable gastric pentadecapeptide BPC 157. Curr Pharm Des 2011;17:1612–32.
Chang CH et al. The promoting effect of BPC 157 on tendon healing. J Appl Physiol 2011;110:774–80.
Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med 2005;11:421–9.
Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide. Int J Mol Sci 2018;19:1987.
On the combination itself — no published study has tested these peptides together in humans or animals. The blend is a convenience, not a researched protocol.
Regulatory status — no component is approved by SAHPRA or the FDA. BPC-157 and TB-500 are on the WADA prohibited list.
Educational reference only
This document is a research reference, not medical advice and not a treatment plan. No component of this blend is approved by SAHPRA, and the combination itself has never been studied. Dose decisions belong to you and your prescriber. Independent certificates of analysis for every LA LAB batch are published under Research → Lab Results, with the Janoshik task number and verification key so you can check them yourself.